Literature DB >> 8144511

Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop.

G F Alberts1, K A Peifley, A Johns, J F Kleha, J A Winkles.   

Abstract

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide originally purified from endothelial cell-conditioned medium. It has multiple biological activities and has been implicated in a number of human diseases, including hypertension and atherosclerosis. Contradictory reports have been published regarding whether ET-1 is a mitogen for vascular smooth muscle cells (SMC); thus, this issue is presently unresolved. In this study, we demonstrate that rat aortic SMC express functional endothelin cell surface receptors but do not proliferate when ET-1 is added to serum-free culture medium on every other day for a period of 1 week. To determine whether ET-1 could function in an autocrine manner to promote SMC growth, we transfected this same cell line with an ET-1 expression plasmid. Several independent lines expressing variable levels of ET-1 mRNA and biologically active ET-1 were obtained. Cell proliferation assays indicated that the transfected SMC line secreting the highest level of ET-1 had an enhanced growth rate when compared with untransfected or vector-alone transfected cells. The growth rate of this SMC line, but not of untransfected cells, was significantly reduced when the ETA receptor subtype-selective antagonist BQ-123 was included in the culture medium. These results indicate that constitutive ET-1 overexpression can promote SMC proliferation. Therefore, it is possible that under certain conditions ET-1 could be an important factor controlling SMC replication in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144511

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Decreased adrenomedullin production in the coronary circulation of patients with coronary artery disease.

Authors:  Y Hojo; U Ikeda; T A Katsuki; K Shimada
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 4.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

6.  The expression of angiotensin and endothelin system members in bovine corpus luteum during estrous cycle and pregnancy.

Authors:  Bajram Berisha; Dieter Schams; Akio Miyamoto
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

7.  Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk.

Authors:  Katsuhito Yasuno; Mehmet Bakırcıoğlu; Siew-Kee Low; Kaya Bilgüvar; Emília Gaál; Ynte M Ruigrok; Mika Niemelä; Akira Hata; Philippe Bijlenga; Hidetoshi Kasuya; Juha E Jääskeläinen; Dietmar Krex; Georg Auburger; Matthias Simon; Boris Krischek; Ali K Ozturk; Shrikant Mane; Gabriel J E Rinkel; Helmuth Steinmetz; Juha Hernesniemi; Karl Schaller; Hitoshi Zembutsu; Ituro Inoue; Aarno Palotie; François Cambien; Yusuke Nakamura; Richard P Lifton; Murat Günel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

8.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease.

Authors:  Ivan Dimitrijevic; Marie-Louise Edvinsson; Qingwen Chen; Malin Malmsjö; Per-Ola Kimblad; Lars Edvinsson
Journal:  BMC Cardiovasc Disord       Date:  2009-08-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.